Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (51-60 of 174) with videos related to

Pageof 18
Sort By:
Cancers|February 11, 2023
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective StudyAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Cancer|April 22, 2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimensGiulia Benevolo, Alessandra Larocca, Massimo Gentile, et al.
European Journal of Haematology|May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Cancers|May 7, 2019
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib TherapyGiulia Bruno, Sara Bringhen, Ilaria Maffei, et al.
Blood|February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years laterAntonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
Leukemia Research|April 21, 2009
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effectsAlessandro Corso, Patrizia Zappasodi, Luciana Barbarano, et al.
Cancers|February 25, 2023
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center ExperienceGiulia Mingrone, Anna Astarita, Anna Colomba, et al.
American Journal of Hematology|September 10, 2025
European Myeloma Network Consensus Statement on Functional High-Risk Multiple MyelomaSueh-Li Lim, Monika Engelhardt, Evangelos Terpos, et al.
Frontiers in Oncology|March 27, 2025
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature reviewFrancesca Gay, Elena Zamagni, Craig Emmitt Cole, et al.
Cancers|December 6, 2024
Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. <i>Cancers</i> 2024, <i>16</i>, 3081Anna Colomba, Anna Astarita, Giulia Mingrone, et al.
Pageof 18

Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Cancers|February 11, 2023
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective StudyAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Cancer|April 22, 2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimensGiulia Benevolo, Alessandra Larocca, Massimo Gentile, et al.
European Journal of Haematology|May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Cancers|May 7, 2019
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib TherapyGiulia Bruno, Sara Bringhen, Ilaria Maffei, et al.
Blood|February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years laterAntonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
Leukemia Research|April 21, 2009
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effectsAlessandro Corso, Patrizia Zappasodi, Luciana Barbarano, et al.
Cancers|February 25, 2023
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center ExperienceGiulia Mingrone, Anna Astarita, Anna Colomba, et al.
American Journal of Hematology|September 10, 2025
European Myeloma Network Consensus Statement on Functional High-Risk Multiple MyelomaSueh-Li Lim, Monika Engelhardt, Evangelos Terpos, et al.
Frontiers in Oncology|March 27, 2025
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature reviewFrancesca Gay, Elena Zamagni, Craig Emmitt Cole, et al.
Cancers|December 6, 2024
Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. <i>Cancers</i> 2024, <i>16</i>, 3081Anna Colomba, Anna Astarita, Giulia Mingrone, et al.
Pageof 18